CoChat

GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis

Open access

Published version of a preprint

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Increasing evidence indicates that obesity is highly associated with chronic kidney disease (CKD). GLP-1 receptor (GLP-1R) agonist has shown benefits on kidney diseases, but its direct role on kidney metabolism in obesity is still not clear. This study aims to investigate the protection and metabolic modulation role of liraglutide (Lira) on kidney of obesity. Rats were induced obese by high-fat diet (HFD), and renal function and metabolism changes were evaluated by metabolomic, biological and histological methods. HFD rats exhibited systemic metabolic disorders such as obesity, hyperlipidemia and impaired glucose tolerance, as well as renal histological and function damages, while Lira significantly ameliorated these adverse effects in HFD rats. Metabolomic data showed that Lira directly reduced renal lipids including fatty acid residues, cholesterol, phospholipids and triglycerides, and improved mitochondria metabolites such as succinate, citrate, taurine, fumarate and nicotinamide adenine dinucleotide (NAD+) in the kidney of HFD rats. Furthermore, we revealed that Lira inhibited renal lipid accumulation by coordinating lipogenic and lipolytic signals, and partly rescued renal mitochondria function via Sirt1/AMPK/PGC1α pathways in HFD rats. This study suggested that Lira alleviated HFD-induced kidney injury at least partly via directly restoring renal metabolism, thus GLP-1R agonist is a promising therapy for obesity-associated CKD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0193473

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 (A)Representative HE, PAS staining (scale bar = 50 μm) and IHC staining for α-SMA (scale bar = 100 μm) of kidney from control, HFD and HFD + Lira group. (B) IHC staining for IL-6 and MCP-1 in kidney of different groups (scale bar = 100 μm). (C)Quantification of IL-6 and MCP-1 protein detected by IHC staining. (D-E) Morphological analysis of glomerular size, glomerulosclerosis and interstitial fibrosis in renal sections. (F)Quantification of α-SMA detected by IHC staining(** p<0.01, compared with control;# p<0.05,# # p<0.01, compared with HFD).
Fig 1 (A)Representative HE, PAS staining (scale bar = 50 μm) and IHC staining for α-SMA (scale bar = 100 μm) of kidney from control, HFD and HFD + Lira group. (B) IHC staining for IL-6 and MCP-1 in kidney of different groups (scale bar = 100 μm). (C)Quantification of IL-6 and MCP-1 protein detected by IHC staining. (D-E) Morphological analysis of glomerular size, glomerulosclerosis and interstitial fibrosis in renal sections. (F)Quantification of α-SMA detected by IHC staining(** p<0.01, compared with control;# p<0.05,# # p<0.01, compared with HFD).CC BY · PubMed Central
Fig 2 OPLS-DA loading plots derived from renal lipid extracts of 1H NMR spectra in (A) HFD group vs control group and (B) HFD+ Lira group vs HFD group. Note: 1. Total Cholesterol (C18H3), 2. Fatty acid residues (ω-CH3), 3. Total Cholesterol (C26H3, C27H3), 4. Free Cholesterol (C19H3), 5. Fatty acid residues ((CH2-)n), 6. Fatty acid residues (COCH2-CH2), 7. Fatty acid residues (-CH2 of ARA+EPA), 8. Fatty acid residues (CH2-CH = 9. Fatty acid residues (-CO-CH2), 10. Fatty acid residues (-CH = CH-CH2-CH = CH-), 11. Phosphatidylethanolamine (-CH2-NH2), 12. Sphingomyelin (-CH2-N-(CH3)3), 13, Phosphatidylcholine (-CH2-N-(CH3)3), 14. Total phospholipids (Glycerol (C3H2)), 15. Triglycerides (C1H and C3H of glycerol), 16. Triglycerides(C2H of glycerol), 17. Fatty acid residues (-CH = CH-).
Fig 2 OPLS-DA loading plots derived from renal lipid extracts of 1H NMR spectra in (A) HFD group vs control group and (B) HFD+ Lira group vs HFD group. Note: 1. Total Cholesterol (C18H3), 2. Fatty acid residues (ω-CH3), 3. Total Cholesterol (C26H3, C27H3), 4. Free Cholesterol (C19H3), 5. Fatty acid residues ((CH2-)n), 6. Fatty acid residues (COCH2-CH2), 7. Fatty acid residues (-CH2 of ARA+EPA), 8. Fatty acid residues (CH2-CH = 9. Fatty acid residues (-CO-CH2), 10. Fatty acid residues (-CH = CH-CH2-CH = CH-), 11. Phosphatidylethanolamine (-CH2-NH2), 12. Sphingomyelin (-CH2-N-(CH3)3), 13, Phosphatidylcholine (-CH2-N-(CH3)3), 14. Total phospholipids (Glycerol (C3H2)), 15. Triglycerides (C1H and C3H of glycerol), 16. Triglycerides(C2H of glycerol), 17. Fatty acid residues (-CH = CH-).CC BY · PubMed Central
Fig 3 OPLS-DA loading plots derived from renal aqueous extracts of 1H NMR spectra in (A) HFD group vs control group and (B) HFD+ Lira group vs HFD group.The colored correlation coefficients indicated significant metabolites which were higher or lower in each group.
Fig 3 OPLS-DA loading plots derived from renal aqueous extracts of 1H NMR spectra in (A) HFD group vs control group and (B) HFD+ Lira group vs HFD group.The colored correlation coefficients indicated significant metabolites which were higher or lower in each group.CC BY · PubMed Central
Fig 4 (A)Oil Red O (ORO) staining of kidney from control, HFD and HFD + Lira group (scale bar = 100 μm).(B) Quantification of kidney MDA level. (C) Real-time PCR analysis for CD36, L-FABP, SREBP-1c, FAS, PPAR-α and CPT1 mRNA. (D) IHC staining for renal PPAR-α, FABP1 and CPT1(scale bar = 100 μm). (E) Quantification of PPAR-α, FABP1 and CPT1proteindetected by IHC staining (* p<0.05, ** p<0.01, compared with control;# p<0.05, # # p<0.01, compared with HFD).
Fig 4 (A)Oil Red O (ORO) staining of kidney from control, HFD and HFD + Lira group (scale bar = 100 μm).(B) Quantification of kidney MDA level. (C) Real-time PCR analysis for CD36, L-FABP, SREBP-1c, FAS, PPAR-α and CPT1 mRNA. (D) IHC staining for renal PPAR-α, FABP1 and CPT1(scale bar = 100 μm). (E) Quantification of PPAR-α, FABP1 and CPT1proteindetected by IHC staining (* p<0.05, ** p<0.01, compared with control;# p<0.05, # # p<0.01, compared with HFD).CC BY · PubMed Central
Fig 5 (A) Fluorescence staining of MitoSOX in kidney from control, HFD and HFD + Lira group (scale bar = 100μm). (B) Quantification of kidney mtROS detected by MitoSOX staining. (C) Renal tissue ATP levels in different groups. (D) Real-time PCR analysis for TFAM, NRF-1, NDUFS5 and SDHB mRNA. (E) IHC staining for renal UCP2 and ATP5a1(scale bar = 100μm). (F) Quantification of UCP2 and ATP5a1protein detected by IHC staining (* p<0.05, ** p<0.01 compared with control; # p<0.05,# # p<0.01 compared with HFD).
Fig 5 (A) Fluorescence staining of MitoSOX in kidney from control, HFD and HFD + Lira group (scale bar = 100μm). (B) Quantification of kidney mtROS detected by MitoSOX staining. (C) Renal tissue ATP levels in different groups. (D) Real-time PCR analysis for TFAM, NRF-1, NDUFS5 and SDHB mRNA. (E) IHC staining for renal UCP2 and ATP5a1(scale bar = 100μm). (F) Quantification of UCP2 and ATP5a1protein detected by IHC staining (* p<0.05, ** p<0.01 compared with control; # p<0.05,# # p<0.01 compared with HFD).CC BY · PubMed Central
Fig 6 (A) IHC staining for PGC1α, p-AMPK and Sirt1of kidney from control, HFD and HFD + Lira group (scale bar = 100μm). (B) Real-time PCR analysis for Sirt1 and PGC1α mRNA. (C) Quantification of PGC1α, p-AMPK and Sirt1 protein detected by IHC staining. (D) Determination of renal NAD+/NADH ratio by commercial kit (** p<0.01 compared with control; # # p<0.01 compared with HFD).
Fig 6 (A) IHC staining for PGC1α, p-AMPK and Sirt1of kidney from control, HFD and HFD + Lira group (scale bar = 100μm). (B) Real-time PCR analysis for Sirt1 and PGC1α mRNA. (C) Quantification of PGC1α, p-AMPK and Sirt1 protein detected by IHC staining. (D) Determination of renal NAD+/NADH ratio by commercial kit (** p<0.01 compared with control; # # p<0.01 compared with HFD).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 110

Metadata

Authors
Wang, C., Li, L., Liu, S., Liao, G., Li, L., Chen, Y., Cheng, J., Lu, Y., & Liu, J.
Affiliations
Sichuan University (CN)
Corresponding author
  • Lu, Yanrong
  • Liu, Jingping
Venue
PLOS ONE
Published
2018-03-28
Volume
13
Issue
3
Pages
e0193473
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2795005430
Cited by
110
References
48
Citations by year
2026: 15 · 2025: 14 · 2024: 13 · 2023: 12 · 2022: 14 · 2021: 14 · 2020: 15 · 2019: 12 · 2018: 1
FWCI
8.60
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Natural Science Foundation of China (31200754, 81571808)
  • China Postdoctoral Science Foundation (2012M511931)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
GLP-1 receptor agonists, liraglutide, obesity, chronic kidney disease, renal metabolism, high-fat diet, renal lipid accumulation, mitochondrial function, hyperlipidemia, impaired glucose tolerance
MeSH terms
Liraglutide, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Fibrosis, Homeostasis, Kidney, Male, Mitochondria, Obesity, Signal Transduction, Rats, Sprague-Dawley, Lipid Metabolism, Rats, AMP-Activated Protein Kinases, Metabolomics, Sirtuin 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.